Monthly Archives: January 2017

­

Immuron Initiates NASH MOA Studies with SanyalBio and with Duke University

MELBOURNE, Australia, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce the initiation of several studies designed to add to the growing body of evidence supporting the unique mechanism of action (MOA) of IMM-124E in non-alcoholic steatohepatitis (NASH). The studies will be done in partnership with Sanyal Biotechnology [...]

January 24th, 2017|News|0 Comments